Archives of Cardiovascular Diseases最新文献

{"title":"About the SFC","authors":"","doi":"10.1016/S1875-2136(26)00328-1","DOIUrl":"10.1016/S1875-2136(26)00328-1","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 8","pages":"Page iii"},"PeriodicalIF":2.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurodevelopment at 24 months of age of children born preterm with congenital heart disease","authors":"Amélie Robinet, Oscar Werner, Alban-Elouen Baruteau, Bénédicte Gaillard Le Roux, Cyril Flamant, Valerie Rouger, Ghislain Leduc, Nicolas Joram, Chenouard Alexis, Pierre Bourgoin","doi":"10.1016/j.acvd.2026.06.043","DOIUrl":"10.1016/j.acvd.2026.06.043","url":null,"abstract":"<div><h3>Introduction</h3><div>Newborns with congenital heart disease (CHD) and preterm newborns are at high risk for morbi-mortality. However, the extent to which CHD affects long-term outcomes, especially neurodevelopment, in preterm newborns remains unclear.</div></div><div>Newborns with congenital heart disease (CHD) and preterm newborns are at high risk for morbi-mortality. However, the extent to which CHD affects long-term outcomes, especially neurodevelopment, in preterm newborns remains unclear.</div><div><h3>Methods</h3><div>Retrospective case control matched study. Preterm infants (<<!--> <!-->37 weeks of gestation) born with CHD between January 2013 and December 2022 included in the LIFT cohort and followed up at 24 months were matched 4:1 by gender, gestational age, year and place of birth and parental socio-professional status.</div></div><div>Retrospective case control matched study. Preterm infants (<<!--> <!-->37 weeks of gestation) born with CHD between January 2013 and December 2022 included in the LIFT cohort and followed up at 24 months were matched 4:1 by gender, gestational age, year and place of birth and parental socio-professional status.</div><div><h3>Results</h3><div>35 patients with significant CHD were matched with 132 preterm patients without CHD from the LIFT cohort. Severe to moderate neurodevelopmental impairment (NI) was more frequent for patients born preterm with CHD at 24 months of age (12/35 (34.29%) vs 16/132 (12.9%); <em>P</em> <!-->=<!--> <!-->0.0073). Severe NI (14.29% vs 4%, <em>P</em> <!-->=<!--> <!-->0.042) and physician reported motor or cognitive anomalies were also more common. Global ASQ and gross motor ASQ were lower in the CHD group. In an univariate model, unfavorable socio-economic level (OR 2.12, 95% CI [1.07, 4.18]), presence of CHD (OR 3.52, 95% CI [1.47, 8.43]) and duration of invasive ventilation (OR 1.08, 95% CI [1.02–1.15]) were associated with NI at 24 months in preterm infants. Duration of ventilation was associated with NI in multivariate analysis (OR 1.14, 95% CI [1.04, 1.24]).</div></div><div>35 patients with significant CHD were matched with 132 preterm patients without CHD from the LIFT cohort. Severe to moderate neurodevelopmental impairment (NI) was more frequent for patients born preterm with CHD at 24 months of age (12/35 (34.29%) vs 16/132 (12.9%); <em>P</em> <!-->=<!--> <!-->0.0073). Severe NI (14.29% vs 4%, <em>P</em> <!-->=<!--> <!-->0.042) and physician reported motor or cognitive anomalies were also more common. Global ASQ and gross motor ASQ were lower in the CHD group. In an univariate model, unfavorable socio-economic level (OR 2.12, 95% CI [1.07, 4.18]), presence of CHD (OR 3.52, 95% CI [1.47, 8.43]) and duration of invasive ventilation (OR 1.08, 95% CI [1.02–1.15]) were associated with NI at 24 months in preterm infants. Duration of ventilation was associated with NI in multivariate analysis (OR 1.14, 95% CI [1.04, 1.24]).</div><div><h3>Conclusion</h3><div>Pre","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 8","pages":"Page S259"},"PeriodicalIF":2.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing the neurodevelopmental risk in congenital heart disease infants and children in France: A nationwide snapshot","authors":"Marie Soulard, Oscar Werner, Olivier Cadeau, Amanda Guerra, Bénédicte Gaillard Le Roux, Pierre Bourgoin, Anne Chauviré-Drouard, Nicolas Joram, Arnaud Roy, Alban-Elouen Baruteau","doi":"10.1016/j.acvd.2026.06.036","DOIUrl":"10.1016/j.acvd.2026.06.036","url":null,"abstract":"<div><h3>Introduction</h3><div>Neurodevelopmental disorders (NDD) are the most common morbidity in congenital heart disease (CHD) patients across the lifespan. We aim to describe current clinical practice in neuromonitoring and neurodevelopmental follow-up strategies in France.</div></div><div>Neurodevelopmental disorders (NDD) are the most common morbidity in congenital heart disease (CHD) patients across the lifespan. We aim to describe current clinical practice in neuromonitoring and neurodevelopmental follow-up strategies in France.</div><div><h3>Methods</h3><div>An audit using an online nationwide survey was distributed through appropriate healthcare networks and scientific societies.</div></div><div>An audit using an online nationwide survey was distributed through appropriate healthcare networks and scientific societies.</div><div><h3>Results</h3><div>Replies from 100 professionals (25 centers) including 52 physicians working in one of the 10 French surgical CHD centers, were analyzed. Preoperative neuromonitoring is little performed (fetal brain imaging: 2/10 centers, baseline cerebral near-infrared spectroscopy [NIRS]: 2/10 centers, preoperative neurological examination: 4/10 centers). All centers use cerebral NIRS for intraoperative neuromonitoring and early postoperative neuromonitoring. Eighty percent of centers give access to a perinatal healthcare network for longitudinal follow-up up to the age of 7 years, whilst only 1/10 centers keep offering a specialized and multidisciplinary care pathway involving serial neurodevelopmental assessment after the age of 7.</div></div><div>Replies from 100 professionals (25 centers) including 52 physicians working in one of the 10 French surgical CHD centers, were analyzed. Preoperative neuromonitoring is little performed (fetal brain imaging: 2/10 centers, baseline cerebral near-infrared spectroscopy [NIRS]: 2/10 centers, preoperative neurological examination: 4/10 centers). All centers use cerebral NIRS for intraoperative neuromonitoring and early postoperative neuromonitoring. Eighty percent of centers give access to a perinatal healthcare network for longitudinal follow-up up to the age of 7 years, whilst only 1/10 centers keep offering a specialized and multidisciplinary care pathway involving serial neurodevelopmental assessment after the age of 7.</div><div><h3>Conclusion</h3><div>Although all surgical CHD centers perform perioperative and early postoperative neuromonitoring, there is a huge heterogeneity in preoperative neuromonitoring and in the long-term follow-up modalities. This should encourage surgical CHD centers to standardize their practice for both clinical and research purposes.</div></div><div>Although all surgical CHD centers perform perioperative and early postoperative neuromonitoring, there is a huge heterogeneity in preoperative neuromonitoring and in the long-term follow-up modalities. This should encourage surgical CHD centers to standardize their practice for both clini","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 8","pages":"Page S256"},"PeriodicalIF":2.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long term results of percutaneous perimembraneous ventricular septal defect closure with the new era devices","authors":"Houeijeh Ali, François Godart, Olivia Domanski, Alexandre Delarue, Mona Kettroussi, Bouzguenda Ivan, Maxime Lemaitre, Florence Mycinski, Ali Houeijeh","doi":"10.1016/j.acvd.2026.06.054","DOIUrl":"10.1016/j.acvd.2026.06.054","url":null,"abstract":"<div><h3>Introduction</h3><div>Transcatheter closure of perimembranous ventricular septal defects (pmVSD) has emerged as a less invasive alternative to surgery. Long-term safety remains a concern, particularly regarding conduction disturbances.</div><div>The aim of this study is to evaluate the long-term outcomes after transcatheter pmVSD closure using new-generation devices in a single-center cohort.</div></div><div>Transcatheter closure of perimembranous ventricular septal defects (pmVSD) has emerged as a less invasive alternative to surgery. Long-term safety remains a concern, particularly regarding conduction disturbances.</div><div>The aim of this study is to evaluate the long-term outcomes after transcatheter pmVSD closure using new-generation devices in a single-center cohort.</div><div><h3>Methods</h3><div>We conducted a retrospective, single-center study including consecutive patients who underwent transcatheter pmVSD closure between Jan 2014 and Dec 2022. Inclusion required<!--> <!-->≥<!--> <!-->3<!--> <!-->years of follow-up with available clinical, ECG, and echocardiographic data. Holter monitoring was performed when clinically indicated.</div></div><div>We conducted a retrospective, single-center study including consecutive patients who underwent transcatheter pmVSD closure between Jan 2014 and Dec 2022. Inclusion required<!--> <!-->≥<!--> <!-->3<!--> <!-->years of follow-up with available clinical, ECG, and echocardiographic data. Holter monitoring was performed when clinically indicated.</div><div><h3>Results</h3><div>A total of 33 patients were included. Median age at the procedure was 25 years [16–39], with 12 patients (36.4%)<!--> <!--><<!--> <!-->18<!--> <!-->years, 24 patients (72.2%) were male. Devices used were Konar-MF in 23 patients (68.8%), Nit- Occlud in 9 (28.1%), and ADO II in 1 (3.1%). Median follow-up was 3.82 years, ranging from 3 to 10 years. An immediate residual shunt was observed in 18 patients (54.5%), including 14 intra-device and 4 para-device shunts. At last follow-up, only 4 patients had a small residual shunt (3 intra-device, 1 para-device), all hemodynamically insignificant with no indication for reintervention. Baseline aortic regurgitation was present in 8 patients (24.2%), including 4 cases associated with Laubry–Pezzi syndrome. No sustained worsening of aortic regurgitation occurred. Early transient conduction disturbances occurred in 2 patients (6.1%) (first or second degree atrioventricular block) and resolved. One patient (3.3%) developed symptomatic late complete atrioventricular block (cAVB) requiring permanent pacemaker implantation approximately 2 years after the procedure; this patient had pre-existing complete left bundle branch block. No case of infective endocarditis was observed. Left ventricular dimensions decreased over the follow-up, with the mean left ventricular end-diastolic diameter <em>Z</em>-score declining from 2.0 before the intervention to 0.9.</div></div><div>A total of 33 ","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"119 8","pages":"Pages S264-S265"},"PeriodicalIF":2.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148816015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive score for supraventricular arrhythmia after patent foramen ovale percutaneous closure.","authors":"Louis Giovachini, Marie Hauguel-Moreau, Claire Dauphin, Mikael Laredo, Nicolas Meneveau, Meyer Elbaz, Patrick Ohlmann, Jeremie Abtan, Jules Mesnier, Florent Huang, Vincent Auffret, Paul Barsoum, Jean-Michel Clerc, Jean-Noël Andarelli, Farzin Beygui, Antoine Da Costa, Paul Gabrion, Michel Zeitouni, Thomas Rolland, Nadjib Hammoudi, Johanne Silvain, Eric Vicaut, Gilles Montalescot, Paul Guedeney","doi":"10.1016/j.acvd.2026.07.001","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.07.001","url":null,"abstract":"<p><strong>Background: </strong>Supraventricular arrhythmia (SVA) is the most frequent complication after patent foramen ovale (PFO) percutaneous closure.</p><p><strong>Aim: </strong>To develop and validate a predictive score for SVA after PFO closure.</p><p><strong>Methods: </strong>Patients with PFO closure and undergoing implantable loop recorder (ILR) monitoring were recruited in 15 French centres. The primary outcome was any SVA lasting ≥30 s within 3 months after the procedure. The score was derived from multivariable logistic regression from a training set of patients and was tested in an independent internal validation set. The score was then externally validated in a cohort of patients without ILR monitoring from the AIR FORCE registry.</p><p><strong>Results: </strong>Overall, 338 patients undergoing ILR monitoring (270 in the training set; 68 in the internal validation set) and 2215 not undergoing ILR monitoring (external validation set) were included. Determinants of the prognostic score were age, male sex, RoPE score, septum secundum thickness, left atrial volume and device left disc diameter. In the internal validation set, the area under the curve was 0.72 (0.58-0.87). A threshold of 55 (fourth quartile of the training set score) had a specificity of 93.3% and a positive predicted value of 72.7%. In the external validation set, the score demonstrated a similar correlation, with an observed threefold increase in the symptomatic SVA rate between the first and fourth quartiles.</p><p><strong>Conclusions: </strong>This easily calculable score can be used to identify patients at high risk of developing SVA after PFO closure and may help detect candidates for a specific rhythm-monitoring strategy.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148852040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intercentre heterogeneity and determinants of implantable cardioverter-defibrillator technology selection in France.","authors":"Fawzi Kerkouri, Marc Badoz, Rodrigue Garcia, Jules Ader, Frédéric Anselme, Geraldine Bertaux, Laure Champ-Rigot, Pascal Defaye, Jean-Claude Deharo, Camille Delahaye, Charles Guenancia, Jérôme Hourdain, Pierre Khattar, Jacques Mansourati, Christelle Marquié, Jean-Luc Pasquié, Nicolas Sadoul, Marc Strik, Vincent Probst, Serge Boveda, Eloi Marijon","doi":"10.1016/j.acvd.2026.06.075","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.06.075","url":null,"abstract":"<p><strong>Background: </strong>With the recent introduction of the extravascular implantable cardioverter-defibrillator (EV-ICD), clinicians now have three distinct devices for sudden cardiac death prevention: the transvenous implantable cardioverter-defibrillator (TV-ICD); the subcutaneous implantable cardioverter-defibrillator (S-ICD); and the EV-ICD.</p><p><strong>Aims: </strong>To quantify intercentre heterogeneity in device choice, and identify patient characteristics independently associated with selecting a TV-ICD, an S-ICD or an EV-ICD.</p><p><strong>Methods: </strong>We conducted a cross-sectional vignette-based survey across 15 French implanting centres. Centres selected a first-line implantable cardioverter-defibrillator for 21 standardized scenarios in which all three devices were feasible (315 centre-level decisions).</p><p><strong>Results: </strong>Intercentre agreement on device choice was slight (κ=0.065), and the median per-vignette majority consensus was 53% (range: 40-93%), indicating substantial between-centre heterogeneity. Unsupervised clustering of centres identified three distinct selection strategies: a TV-ICD first cluster (5/15 centres; TV-ICD 51.4% of choices); an S-ICD first cluster (7/15 centres; S-ICD 68.7% of choices); and an EV-ICD forward cluster (3/15 centres; EV-ICD 81.0% of choices). In adjusted analyses, age<65years was associated with selection of both S-ICDs (odds ratio [OR]: 2.10, 95% confidence interval [95% CI]: 1.11-4.00; P=0.024) and EV-ICDs (OR: 2.27, 95% CI: 1.05-4.91; P=0.038) versus TV-ICDs. Low body mass index (17 vs. 25kg/m²) was associated with lower odds of selection of an S-ICD versus a TV-ICD (OR: 0.30, 95% CI: 0.09-0.94; P=0.039) and higher odds of selection of an EV-ICD versus an S-ICD (OR: 3.81, 95% CI: 1.27-11.44; P=0.017). Sex, heart disease and prevention setting were not independently associated with device selection.</p><p><strong>Conclusions: </strong>Implantable cardioverter-defibrillator selection showed a marked centre-level practice effect, and was also influenced by age and body mass index. These findings support harmonized selection pathways to reduce unwarranted variability, while preserving patient profile-oriented shared decision-making.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148632904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world use of abbreviated dual antiplatelet therapy after percutaneous coronary intervention among patients with high bleeding risk: Are guidelines followed? Insights from the FRANCE-PCI registry.","authors":"Manveer Singh, Etienne Puymirat, Christophe Robin, Thibault Perret, Franck Barbou, Erwan Bressollette, Youcef Afifi, Gauthier Mouillet, Sébastien Hess, François Tarragano, Akram Chmait, Nicolas Meneveau, Nizar Ben Mansour, Stéphane Rias, Tahar Lazizi, Stephan Chassaing, Guillaume Cayla, Philippe Commeau, Hakim Benamer, Michel Zeitouni, René Koning, Pascal Motreff, Eric Van Belle, Céline Lambert, Grégoire Rangé","doi":"10.1016/j.acvd.2026.06.003","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.06.003","url":null,"abstract":"<p><strong>Background: </strong>Dual antiplatelet therapy reduces ischaemic complications after percutaneous coronary intervention, but increases bleeding risk, especially in patients who are already at high bleeding risk. Current guidelines therefore recommend abbreviated dual antiplatelet therapy in this population.</p><p><strong>Aim: </strong>To evaluate the real-world use of abbreviated dual antiplatelet therapy (≤3 months) after percutaneous coronary intervention according to bleeding risk, using data from the nationwide FRANCE-PCI registry.</p><p><strong>Methods: </strong>All consecutive patients undergoing percutaneous coronary intervention for either acute or chronic coronary syndrome between 2014 and 2023 across 56 hospitals, who were alive at 1 year, and in whom dual antiplatelet therapy duration was known, were included. High bleeding risk was defined as the presence of at least one of the following: age≥75 years; chronic oral anticoagulant therapy; previous stroke; or chronic kidney disease.</p><p><strong>Results: </strong>Among 115,992 patients included, 41.4% met the criteria for high bleeding risk. Abbreviated dual antiplatelet therapy was prescribed in 23.1% of patients with a high bleeding risk versus 3.6% of patients without a high bleeding risk. Among patients with a high bleeding risk, factors independently associated with prolonged (>3 months) dual antiplatelet therapy use were: increasing age (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.02-1.03); female sex (OR 1.18, 95% CI 1.11-1.25); diabetes mellitus (OR 1.15, 95% CI 1.08-1.22); previous stroke (OR 1.54, 95% CI 1.39-1.69); chronic kidney disease (OR 1.24, 95% CI 1.15-1.34); acute coronary syndrome (OR 1.52, 95% CI 1.44-1.61); and stent length≥60mm (OR 1.18, 95% CI 1.09-1.28).</p><p><strong>Conclusions: </strong>In real-word practice, less than one third of patients with a high bleeding risk received abbreviated dual antiplatelet therapy after percutaneous coronary intervention. The use of prolonged dual antiplatelet therapy remained driven by ischaemic risk markers, highlighting persistent uncertainty in bleeding risk/ischaemic risk trade-offs.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148426799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the aortic rim: Additional considerations in risk stratification for transcatheter atrial septal defect closure. Letter in response to the article entitled \"Transcatheter closure of ostium secundum atrial septal defects in 2253 children and adults: Early outcomes\" by Albenque et al.","authors":"Teruhiko Imamura","doi":"10.1016/j.acvd.2026.05.004","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.05.004","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148413924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lessons learned during my collaboration with Alain Carpentier: A 25-year perspective.","authors":"Alain Berrebi","doi":"10.1016/j.acvd.2026.06.001","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.06.001","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148377528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to \"Beyond the aortic rim: Additional considerations in risk stratification for transcatheter atrial septal defect closure\", a letter from Teruhiko Imamura commenting on the article entitled \"Transcatheter closure of ostium secundum atrial septal defects in 2253 children and adults: Early outcomes\" by Albenque et al.","authors":"Grégoire Albenque, Clément Batteux, Sébastien Hascoët","doi":"10.1016/j.acvd.2026.06.002","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.06.002","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148383243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}